AKI Therapeutics A/S: Financial statements 2023
CVR: 37509736
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 0 and a net result of DKK -1,708,694 compared with DKK -1,117,346 the year before. Equity in the 2023 report amounted to DKK 746,586. The solvency ratio was 37.5%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,708,694
- Equity
- DKK 746,586
- Total Assets
- DKK 1,992,951
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 | 0 | -1.7M | 747K | - |
| 2022 | 0 | 0 | -1.1M | 2.5M | - |
| 2021 | 0 | -12K | -1.5M | 3.6M | - |
| 2020 | - | -89K | 148K | 115K | - |
| 2019 | - | -127K | 28K | 52K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 5, 2023, FINANSMANAGEMENT ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 5%.
AKI Therapeutics A/S has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -1,117,346.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.
